Andrew Nichols

Title: Innovations of Andrew Nichols in Antigen Binding Proteins

Introduction

Andrew Nichols is an accomplished inventor based in Calabasas, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of low-viscosity antigen binding proteins. With a total of 2 patents, his work has the potential to impact therapeutic applications significantly.

Latest Patents

Nichols' latest patents focus on methods for preparing antigen binding proteins with reduced viscosity. The first patent details a method for creating antigen binding proteins specific for PCSK9 by replacing residues in high viscosity variable domain subfamilies with those in correlating low viscosity subfamilies. This innovative approach also involves substituting residues in the Fc domain with low viscosity-associated residues and adding charged residues to the C-terminus of the Fc domain. The second patent mirrors this methodology, emphasizing the importance of reducing viscosity in antigen binding proteins to enhance their efficacy.

Career Highlights

Andrew Nichols is currently employed at Amgen Inc., a leading biotechnology company known for its innovative therapies. His work at Amgen has allowed him to focus on groundbreaking research that addresses critical health challenges. Nichols' expertise in protein engineering has positioned him as a key contributor to advancements in therapeutic proteins.

Collaborations

Nichols collaborates with talented professionals in his field, including Joon Hoi Huh and Riki Stevenson. These collaborations foster an environment of innovation and creativity, leading to the development of cutting-edge solutions in biotechnology.

Conclusion

Andrew Nichols is a notable inventor whose work in low-viscosity antigen binding proteins showcases his commitment to advancing biotechnology. His patents and collaborations reflect a dedication to improving therapeutic options for patients.